ETF Managers Group, LLC X Biotech Inc. Transaction History

ETF Managers Group, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$3.58 - $5.88 $2,273 - $3,733	-635 Reduced 6.6%	8,982 $33,000
Q2 2022 Aug 15, 2022	BUY	$5.13 - $9.2 $2,031 - $3,643	396 Added 4.29%	9,617 $55,000
Q1 2022 May 13, 2022	BUY	$8.64 - $11.71 $285 - $386	33 Added 0.36%	9,221 $81,000
Q4 2021 Feb 14, 2022	SELL	$10.95 - $16.07 $20,848 - $30,597	-1,904 Reduced 17.17%	9,188 $103,000
Q3 2021 Nov 15, 2021	BUY	$12.95 - $18.24 $29,085 - $40,967	2,246 Added 25.39%	11,092 $146,000
Q2 2021 Aug 16, 2021	SELL	$15.83 - $17.84 $1,852 - $2,087	-117 Reduced 1.31%	8,846 $146,000
Q1 2021 May 17, 2021	SELL	$15.92 - $20.3 $83,882 - $106,960	-5,269 Reduced 37.02%	8,963 $152,000
Q4 2020 Feb 16, 2021	SELL	$15.65 - $19.92 $31,409 - $39,979	-2,007 Reduced 12.36%	14,232 $227,000
Q3 2020 Nov 16, 2020	BUY	$13.97 - $21.16 $109,720 - $166,190	7,854 Added 93.67%	16,239 $308,000
Q2 2020 Aug 14, 2020	BUY	$10.39 - $16.07 $87,120 - $134,746	8,385 New	8,385 $120,000

4.87M

Ticker XBIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,439,300
Market Cap $203M
Description
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical...

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

Stay updated on ETF Managers Group, LLC with notifications on news.